Cholecystokinin-B/gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies
- 1 April 2002
- journal article
- review article
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 32 (2) , 97-109
- https://doi.org/10.1053/snuc.2002.31028
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinomaCancer, 1997
- A comparison of 111In-octreotide and 67Ga scintigraphy in malignant lymphomaNuclear Medicine Communications, 1997
- Radioimmunotherapy of Solid Tumors: A Review "Of Mice and Men"Hybridoma, 1997
- Somatostatin receptor scintigraphy in the staging of lymphomasLeukemia & Lymphoma, 1997
- Somatostatin‐receptor Scintigraphy in Gastroenteropancreatic TumorsAnnals of the New York Academy of Sciences, 1994
- Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 1993
- Somatostatin-Receptor Imaging in the Localization of Endocrine TumorsNew England Journal of Medicine, 1990
- LOCALISATION OF ENDOCRINE-RELATED TUMOURS WITH RADIOIODINATED ANALOGUE OF SOMATOSTATINThe Lancet, 1989
- Potential role of somatostatin analogues in the treatment of cancerEuropean Journal of Clinical Investigation, 1987
- High Density of Somatostatin Receptors in Pituitary Tumors from Acromegalic PatientsJournal of Clinical Endocrinology & Metabolism, 1984